PR001387 (Project)

Description:Background: Nitisinone induced hypertyrosinaemia is well documented in Alkaptonuria (AKU), and there is uncertainty over whether it may contribute to a decline in cognitive function and or mood by altering neurotransmitter metabolism. The aim of this work was to evaluate the impact of nitisinone on the cerebrospinal fluid (CSF) metabolome in a murine model of AKU, with a view to providing additional insight into metabolic changes that occur following treatment with nitisinone. Methods: 17 CSF samples were collected from BALB/c Hgd-/-mice (n=8, treated with nitisinone – 4 mg/L and n=9, no treatment). Samples were diluted 1:1 with deionised water and analysed using a 1290 Infinity II liquid chromatography system coupled to a 6550 quadrupole time-of-flight mass spectrometry (Agilent, Cheadle, UK). Raw data were processed using a targeted feature extraction algorithm and an established in-house accurate mass retention time database. Matched entities (±10 ppm theoretical accurate mass and ±0.3 minutes retention time window) were filtered based on their frequency and variability. Experimental groups were compared using a moderated t-test with Benjamini-Hochberg false-discovery rate adjustment. Results: Tyrosine, acetyl-tyrosine, ?-glutamyl-tyrosine, p-hydroxyphenylacetic acid and 3-(4-hydroxyphenyl)lactic acid were shown to increase in abundance (log2 fold change 2.6-6.9, 3/5 were significant p<0.05) in the mice that received nitisinone. Several other metabolites of interest were matched but no significant differences were observed, including the aromatic amino acids phenylalanine and tryptophan, and monoamine metabolites adrenaline, 3-methoxy-4-hydroxyphenylglycol and octopamine. Conclusions: Evaluation of the CSF metabolome of a murine model of AKU showed a significant difference in the abundance of a limited number of metabolites. None of these have been reported in CSF from a murine model of AKU previously. Moreover this study confirms that some monoamine metabolites do not appear to be altered following nitisinone therapy.
Results found

Linked to

 

Label

Description

 

Project

Metabolomics

Subject

A subject from Metabolomics produced as part of the PR001387 project

Biosample

A biosample from Metabolomics produced as part of the PR001387 project

Biosample

A biosample from Metabolomics produced as part of the PR001387 project

Biosample

A biosample from Metabolomics produced as part of the PR001387 project

Biosample

A biosample from Metabolomics produced as part of the PR001387 project

Biosample

A biosample from Metabolomics produced as part of the PR001387 project

Biosample

A biosample from Metabolomics produced as part of the PR001387 project

Biosample

A biosample from Metabolomics produced as part of the PR001387 project

Biosample

A biosample from Metabolomics produced as part of the PR001387 project


  • Subject

    A subject from Metabolomics produced as part of the PR001387 project


  • Biosample

    A biosample from Metabolomics produced as part of the PR001387 project


  • Biosample

    A biosample from Metabolomics produced as part of the PR001387 project


  • Biosample

    A biosample from Metabolomics produced as part of the PR001387 project


  • Biosample

    A biosample from Metabolomics produced as part of the PR001387 project


  • Biosample

    A biosample from Metabolomics produced as part of the PR001387 project


  • Biosample

    A biosample from Metabolomics produced as part of the PR001387 project


  • Biosample

    A biosample from Metabolomics produced as part of the PR001387 project


  • Biosample

    A biosample from Metabolomics produced as part of the PR001387 project

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.